Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics
Aclaris Therapeutics, Inc. (ACRS)
Today's Latest Price: $3.82 USD
Updated Oct 29 1:40pm
Add ACRS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ACRS Stock Summary
- ACRS's price/sales ratio is 29.51; that's higher than the P/S ratio of 94.24% of US stocks.
- With a year-over-year growth in debt of -63.83%, Aclaris Therapeutics Inc's debt growth rate surpasses merely 3.75% of about US stocks.
- As for revenue growth, note that ACRS's revenue has grown -65.86% over the past 12 months; that beats the revenue growth of just 2.71% of US companies in our set.
- Stocks that are quantitatively similar to ACRS, based on their financial statements, market capitalization, and price volatility, are RESN, CUE, ZYME, IONS, and CLLS.
- ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to www.aclaristx.com.
ACRS Stock Price Chart Interactive Chart >
ACRS Price/Volume Stats
| Current price | $3.82 | 52-week high | $5.04 |
| Prev. close | $3.82 | 52-week low | $0.70 |
| Day low | $3.76 | Volume | 75,911 |
| Day high | $3.84 | Avg. volume | 599,927 |
| 50-day MA | $3.05 | Dividend yield | N/A |
| 200-day MA | $1.88 | Market Cap | 163.20M |
Aclaris Therapeutics, Inc. (ACRS) Company Bio
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Loading social stream, please wait...